Berlin-based venture capital firm Peppermint VenturePartners (PVP) has appointed Johannes Schneider Littfeld to the advisory board of its new Charité Biomedical Fund (CBF).
Schneider Littfeld is corporate vice president and CEO of Neurostimulation of Otto Bock HealthCare, a global orthopedic technology company.
Klaus Stöckemann, a managing director at PVP, said, “We are very proud to have Mr Schneider Littfeld, another internationally experienced industry expert, joining our advisory board. He brings comprehensive sector knowledge and a network from the medical device and the Healthcare Industry to the board. Especially his international experience in marketing & sales but also in M&A will help to accomplish our goals.”
CBF is an independent venture capital fund initiated by PVP and the Charité Foundation. PVP hasaccess to the network and deal flow of the Charité and its international partners. At the same time PVP uses this relationship for the evaluation of investment opportunities and is also sounding partner for the Charité for spinning off new companies.
Current members of the firm’s advisory board include Prof Annette Grüters-Kieslich (Dean of the Charité), Dr Christine Kreiner (serial entrepreneur and CEO of S&VTechnologies), Rainer Christine (former CEO of Amaxa and private investor), Prof Detlev Ganten (former CEO of the Charité and chairman of the board of the ‘Stiftung Charité’) and Dr Bernd Wegener (former CEO of BRAHMS Diagnostic and board member of several healthcare companies).
PVP manages the newly-established Charité Biomedical Fund and the Peppermint VC-1 Fund with total capital under management of more than €50m was established in 2008 by Ingeborg Neumann and Dr Joachim Rautter from Peppermint Holding together with Dr Klaus Stöckemann, a former general partner at the international venture capital firm 3i. The firm is investing in young healthcare companies with a focus on medical devices mainly across Europe.
Copyright © 2012 AltAssets